Compare OneSpan Inc (OSPN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Zimmer Biomet Holdings Inc — how do they compare? OneSpan Inc trades at $18.03 (market cap $662.97M), while Zimmer Biomet Holdings Inc trades at $89.07 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 25.6× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OSPN | ZBH | |
|---|---|---|
Market Cap | $662.97M | $16.95B |
Volume | 616,882 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $18.42 | $103.98 |
52-Week Low | $10.15 | $79.58 |
Typical Hold Time | 18 Days | 89 Days |
Enterprise Value | $632.05M | $24.02B |
Dividend Yield | 2.89% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% in the last session, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal with support at $17 and resistance at $18. Recent Q2 2026 results exceeded expectations with EPS of $0.30 versus $0.231 expected, while the company introduced new authentication technology to drive future growth.
The outlook remains positive given strong analyst support (66.7% buy ratings) and solid financial metrics, though investors should monitor declining cash flow trends and competitive pressures in the cybersecurity sector. The stock presents value opportunity with P/E of 10.16 and ROE of 26.51%, but faces execution risks in maintaining subscription revenue growth.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
